Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171925
Status:
TERMINATED
Last Update Posted:
2012-04-11
First Post:
2005-09-13
Brief Title:
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Status:
TERMINATED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Recruitment in study could not be reached after 8 yrs of recruiting
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells Malignant plasma cells induce osteolytic lesions which is characteristic for progression of multiple myeloma It is the aim of this study to investigate whether zoledronic acid has an influence on the progression of multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None